MAPT and Alzheimer disease: In 2018, the National Institute on Aging and Alzheimer’s Association (NIA-AA) group introduced a research framework in which subjects with positive biomarkers of amyloid β and tau were classified as having AD, regardless of the presence of symptoms [19].